

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

August 8, 2017

Stephen T. Isaacs Chief Executive Officer Aduro Biotech, Inc. 740 Heinz Avenue Berkeley, CA 94710

> Re: Aduro Biotech, Inc. Registration Statement on Form S-3 Filed August 2, 2017 File No. 333-219639

Dear Mr. Isaacs:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Ada D. Sarmento at (202) 551-3798 with any questions.

Division of Corporation Finance Office of Healthcare & Insurance

cc: Michael E. Tenta, Esq.